Agner R. Sanchez-Parra

Amsterdam, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Phosphoinositide 3-kinase δ activity in patients with systemic lupus erythematosus.

Phosphoinositide 3-kinase δ activity in patients with systemic lupus erythematosus.

Journal: Frontiers in immunology

Published: November 13, 2025

Patient-physician discordance in assessing SLE disease activity: longitudinal analysis of disease-related variables and quality of life.

Patient-physician discordance in assessing SLE disease activity: longitudinal analysis of disease-related variables and quality of life.

Journal: Rheumatology (Oxford, England)

Published: July 22, 2025

Failing maternal-fetal tolerance in SLE (FaMaLE): a prospective cohort study for finding the molecular mechanisms behind pregnancy complications.

Failing maternal-fetal tolerance in SLE (FaMaLE): a prospective cohort study for finding the molecular mechanisms behind pregnancy complications.

Journal: Lupus science & medicine

Published: May 16, 2025

Advancing treat-to-target in SLE: a pilot study using a clinical decision support system.

Advancing treat-to-target in SLE: a pilot study using a clinical decision support system.

Journal: Lupus science & medicine

Published: March 26, 2025

Correction: Targeting DORIS Remission and LLDAS in SLE: A Review.

Correction: Targeting DORIS Remission and LLDAS in SLE: A Review.

Journal: Rheumatology and therapy

Published: June 07, 2024

Treat-to-target and shared decision-making in systemic lupus erythematosus from the patients' perspective: results from an international patient survey.

Treat-to-target and shared decision-making in systemic lupus erythematosus from the patients' perspective: results from an international patient survey.

Journal: Clinical and experimental rheumatology

Published: January 12, 2024

Clinical and humoral response after SARS-CoV-2 breakthrough infection in patients receiving immunosuppressant therapy.

Clinical and humoral response after SARS-CoV-2 breakthrough infection in patients receiving immunosuppressant therapy.

Journal: The Journal of allergy and clinical immunology

Published: December 23, 2023

Targeting DORIS Remission and LLDAS in SLE: A Review.

Targeting DORIS Remission and LLDAS in SLE: A Review.

Journal: Rheumatology and therapy

Published: July 05, 2023

Web-based eHealth Clinical Decision Support System as a tool for the treat-to-target management of patients with systemic lupus erythematosus: development and initial usability evaluation.

Web-based eHealth Clinical Decision Support System as a tool for the treat-to-target management of patients with systemic lupus erythematosus: development and initial usability evaluation.

Journal: BMJ health & care informatics

Published: May 24, 2023

Persistence of seroconversion at 6 months following primary immunisation in patients with immune-mediated inflammatory diseases.

Persistence of seroconversion at 6 months following primary immunisation in patients with immune-mediated inflammatory diseases.

Journal: Annals of the rheumatic diseases

Published: October 12, 2022

Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseases.

Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseases.

Journal: Annals of the rheumatic diseases

Published: June 09, 2022

Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies.

Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies.

Journal: The Lancet. Rheumatology

Published: May 09, 2022

Showing 1-12 of 13

Last Updated: 09/26/2026